Globus Medical (NYSE:GMED) Given New $99.00 Price Target at Wells Fargo & Company

Globus Medical (NYSE:GMED) had its price target lowered by investment analysts at Wells Fargo & Company from $103.00 to $99.00 in a report issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the medical device company’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 20.64% from the stock’s previous close.

Several other research firms have also recently commented on GMED. Stifel Nicolaus lowered their target price on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research note on Wednesday, July 8th. Needham & Company LLC upped their price target on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Monday, July 13th. Finally, UBS Group assumed coverage on Globus Medical in a report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Globus Medical currently has an average rating of “Moderate Buy” and an average price target of $101.77.

Globus Medical Stock Performance

Shares of NYSE:GMED traded up $0.98 on Friday, hitting $82.06. The company’s stock had a trading volume of 570,931 shares, compared to its average volume of 1,477,988. Globus Medical has a 12 month low of $54.15 and a 12 month high of $101.40. The company has a market capitalization of $11.14 billion, a price-to-earnings ratio of 19.14, a price-to-earnings-growth ratio of 1.66 and a beta of 0.95. The stock’s 50-day moving average is $79.33 and its two-hundred day moving average is $85.25.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. During the same period last year, the company earned $0.86 earnings per share. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts expect that Globus Medical will post 4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the sale, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 18.38% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Several hedge funds have recently made changes to their positions in GMED. Elevation Wealth Partners LLC raised its holdings in shares of Globus Medical by 2,178.6% in the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock worth $25,000 after purchasing an additional 305 shares in the last quarter. Advisory Services Network LLC bought a new stake in Globus Medical during the third quarter worth approximately $26,000. EverSource Wealth Advisors LLC boosted its holdings in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares in the last quarter. SBI Securities Co. Ltd. grew its position in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares during the last quarter. Finally, Parallel Advisors LLC grew its position in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, versus analyst estimates near $1.10-$1.12, while revenue reached $789.6 million, ahead of the $782.9 million consensus. Earnings increased from $0.86 per share a year earlier, and revenue rose 5.9% year over year. Globus Medical Reports Second Quarter 2026 Results
• Positive Sentiment: Full-year earnings guidance was raised above Wall Street expectations: Management provided fiscal 2026 EPS guidance of $4.95-$5.05, compared with the $4.74 analyst consensus. The higher outlook suggests improved confidence in profitability and execution. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: TD Cowen maintained a Buy rating and $115 price target. Analyst Mathew Blackman cited reaccelerating spine growth, strong earnings power and robust research-and-development investment as reasons for the constructive view. Globus Medical Earns Buy Rating
• Neutral Sentiment: Revenue guidance was broadly in line with consensus at approximately $3.2 billion for fiscal 2026, meaning the main guidance-driven upside came from the improved EPS outlook rather than a sales forecast increase.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.